MedTrace Logo

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

NCT06117085 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-11-21

No results posted yet for this study

Summary

The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.

Conditions

  • Thyroid Nodule (Benign)

Interventions

DEVICE

CellFX® Percutaneous Electrode (PE) System

Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology

Sponsors & Collaborators

  • Pulse Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Prof Stefano Spiezia, MD · Chief of Endocrine and Ultrasound Guided Surgery, Operative Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-13
Primary Completion
2024-11-18
Completion
2024-11-18

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06117085 on ClinicalTrials.gov